About This Study
Infection from the human papillomavirus (HPV) can cause lesions in the anal canal. Those lesions could possibly turn into cancer. The purpose of this study is to find out if VGX-3100 will get rid of those lesions.
Need volunteers who are HIV-positive and have never had cancer of the anus, vulva, vagina, or cervix. Taking part in this study involves four doses of VGX-3100 over 24 weeks. After you get all the doses, your doctor will watch you for side effects and follow your condition for another 48 weeks. Study team will discuss study details with you.
What Activities Are a Part of this Study?
- Informed Consent Review
- Use of Study Treatments or Placebo
- Review of Medical History
- Physical Examinations
- Study Visits and Consultations
- Laboratory and Imaging Tests
- Specimen Sample Collection
- Diary/e-Diary Writing or Recordings
Age & Gender
- 18 - 80 years old
- All Genders
Language
- This study enrolls English and Spanish speakers
Additional Study Information
- Compensation Offered
- No reimbursement offered
Study Locations
- Greater Winston-Salem, NC